NCT06345183 2025-11-06Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) PatientsBristol-Myers SquibbCompleted327 enrolled